Jun 5 |
AstraZeneca completes Fusion Pharmaceuticals acquisition
|
Jun 4 |
Acquisition of Fusion Pharmaceuticals Completed
|
May 31 |
Ontario court approves AstraZeneca/Fusion acquisition plan
|
May 31 |
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
|
May 29 |
Fusion shareholders give green light to AstraZeneca acquisition
|
May 29 |
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
|
May 10 |
Fusion Pharmaceuticals doses first subject in prostate cancer trial
|
May 9 |
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
|
May 7 |
Fusion Pharmaceuticals GAAP EPS of -$0.40
|
May 7 |
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
|